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Abstract: The therapy of complex neurodegenerative diseases 
raises the need for the development of multitarget-directed drugs 
(MTD). Novel MTD indole derivatives with inhibitory potencies at 
acetyl/butyrylcholinesterases and monoamine oxidases A/B as well 
as at the histamine H3 receptor (H3R) were obtained by optimization 
of the neuroprotectant ASS234 by incorporating generally accepted 
H3R pharmacophore motifs. These small molecule hits demonstrated 
balanced activities at the targets, mostly in a nanomolar concentration 
range. Additional in vitro studies showed anti-oxidative, 
neuroprotective and brain penetration effects. With this promising in 
vitro profile, compound contilisant (4 at 1 mg/kg i.p.) also improved 
significantly the lipopolysaccharide-induced cognitive deficits. 
Alzheimer’s (AD) and Parkinson´s diseases (PD) are the most 
prevalent neurodegenerative diseases with complex and variable 
underlying mechanisms. In studies of the causes and in searches 
for more efficient therapies, factors such as mitochondrial 
dysfunction, neuro-inflammation, and especially oxidative stress 
have been identified as major determinants in progress and 
development of these diseases. Consequently, an antioxidant 
drug development strategy for neurodegenerative diseases, 
especially AD, has been of paramount importance.[1,2] A recent 
multitarget-directed ligand (MDL) ASS234 (Figure 1)[3–5] is able to 
irreversibly inhibit monoamine oxidases A and B (MAO A/B), and 
also reduce production of the second product hydrogen peroxide, 
a reactive oxygen species (ROS).[6] Thus, ASS234 prevents the 
catalytic oxidation of biogenic amines, such as serotonin (5-HT), 
norepinephrine and dopamine, all implicated in cognitive 
processes, as well as production of ROS associated with neuronal 
cell death. Additional, ASS234 gives reversible 
acetylcholinesterase (AChE) inhibition, improving memory and 
cognition, comparable to that of marketed AChE inhibitors (e.g. 
donepezil).[7]  
The histamine H3 receptor (H3R) is involved in the central 
regulation of histamine and other neurotransmitters,[8,9] so was 
targeted as useful novel pharmacological tool. Blockade of H3R 
by inverse agonists/antagonists elevates neurotransmitters, like 
acetylcholine (ACh), 5-HT, dopamine or norepinephrine in the 
central nervous system. The first H3R inverse agonist pitolisant 
(WAKIX®) was approved recently for the treatment of narcolepsy, 
but is also under investigation for diverse cognition and sleep 
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impairments.[10] Thus, the pro-cognitive use of H3R 
antagonists/inverse agonists for neurodegenerative disease is 
being investigated.[11] Although compounds showing multipotent 
profiles combining H3R affinity with cholinesterase (ChE) 
inhibition,[12,13] and antioxidant capacity[14] or most recently with 
MAO inhibition[15] have been  reported (for review see [16]), MDLs 
able to modulate simultaneously H3R, MAO and ChE have not 
yet been addressed. This multipotent profile might constitute an 
innovative therapeutic approach for new molecules targeting 
neurodegenerative diseases with multiple causes.  
 
Figure 1. General structure of H3R/MAO/ChE MDLs derived from structural 
elements of antioxidant ASS234 and H3R antagonist ciproxifan. 
ASS234 was structurally modified to fit a generally accepted 
pharmacophore of H3R antagonists (Figure 1). To avoid adverse 
effects associated with imidazole-containing H3R antagonists 
(e.g. ciproxifan), cyclic aliphatic amines like piperidine as the 
basic center were connected via a (propyloxy)phenyl chain to an 
eastern arbitrary region. These compounds provide suitable 
pharmacophores verified by multiple structure-activity relationship 
(SAR) studies.[17–19] Here, we report the synthesis and biological 
evaluation of MDLs 1-7 (Scheme 1), and the identification of 
compound 4 (contilisant) providing high antioxidant activity, high 
affinity at H3R, and excellent inhibition of the target 
neurotransmitter-catabolizing enzymes. These compounds were 
evaluated for their affinity at human H3R, H4R and against four 
neurotransmitter-catabolizing enzymes (AChE and 
butyrylcholinesterase (BuChE), MAO A/B) (for further off-target 
screening see Supporting Information). 
 
Scheme 1. Synthesis of MDLs 1-7. Reagents and conditions: a. NaH, DMF, rt; 
b. PPh3, DIAD, THF, rt; c. K2CO3, DMF, 90 ºC. 
All MDLs in this small series inhibited ChEs in the micromolar 
range (Table 1). Contilisant revealed the best inhibition properties 
with high nanomolar inhibition of AChE. The initial reversible 
inhibition of MAO A/B (reflecting binding) and inhibition after 
30 min preincubation of the inhibitor with the enzymes (due to 
irreversible inhibition) were determined (Table 1). Without 
preincubation, all compounds gave low micromolar IC50 values. 
The spacer lengths influence the binding to the active sites of 
MAO A and B, with a two carbon spacer being optimum when 
bearing a piperidine ring. Switching to a pyrrolidine ring has little 
effect in compounds with a three carbon spacer (2 vs. 4), but 
decreased inhibition in compounds with a two carbon spacer (1 
vs. 3). After preincubation, IC50 values shifted to nanomolar 
concentrations for most of the propargylamines. Irreversible MAO 
inhibition was confirmed for contilisant by 50-fold dilution into 
excess substrate. The IC50 value for compound 6 changed very 
little with preincubation, suggesting that the propargyl group did 
not form a covalent adduct with MAO B. Compound 7, lacking the 
propargyl group, showed no change with preincubation. MAO 
activity after 50-fold dilution of 7 was >95%, indicating reversible 
inhibition. Contilisant, showed improved irreversible inhibition of 
MAO B compared to the MAO A-preferring ASS234. The affinity 
for binding at human H3R as target and H4R, the structurally most 
homologous G-protein-coupled receptor, as off-target were 
measured (Table 1). None of the compounds bound to H4R, 
indicating good specificity for H3R. Surprisingly, ASS234 showed 
a remarkable affinity at H3R, but highest affinity was found for 2 
and contilisant, both containing the propyloxy linker connected to 
pyrrolidino and piperidino moieties, respectively. Good affinities 
were also found for 6, containing a related H3R pharmacophore 
motif, and 7, lacking the propargyl amine group but preserving the 
propyloxy linker. Compounds with ethyloxy or pentyloxy spacer 
showed moderate H3R affinities. These findings confirm 
previously obtained SAR for H3R antagonists.[17,20,21] Since 
compounds 6 and 7 exhibit comparable H3R affinity, we could 
demonstrate, that the H3R affinity is positively influenced by the 
introduction of the second basic moiety, the propargylamine motif, 
that gives the MAO inactivation properties. Compound 6, although 
less effective against AChE, provides structural variation 
possibilities as the MAO motif could be combined with varied 
spacers or amine warheads for H3R pharmacophore.  
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Molecular docking studies on the four targets clearly support the 
in vitro data findings since ASS234 and contilisant fit to the 
diverse binding cavities for AChE, MAO A/B and H3R (see 
Supporting Information). Notably in the molecular properties of 
contilisant obtained with molsoft[26] is its higher hydrophilicity 
(MolLogP = 3.7) compared to that of ASS234 (MolLogP = 5.5), 
confirming increased drug-likeness. Further indication for central 
distribution was obtained from the parallel artificial membrane 
permeability assay (PAMPA), a tool for prediction of the blood 
brain barrier (BBB) penetration properties (see Supporting 
Information). Results clearly indicated the ability of contilisant and 
ASS234 to pass the BBB via passive diffusion. A complete in 
silico ADME analysis of the novel hybrids 1-7 has been carried 
out suggesting drug suitability, with special focus to contilisant 
(see Supporting Information). The antioxidant capacity of hybrids 
1-5, and 7 was measured as oxygen radical absorbance capacity 
(ORAC-FL) (Table 1),[27] with all MDLs presenting good radical 
scavenging properties, with those for contilisant close to that of 
the positive control ferulic acid (3.74±0.22 TE).[28] Neuroprotection 
capacity was studied using three different toxic insults involved in 
neurodegeneration mechanisms in AD:[29] (a) cocktail of 
mitochondrial respiratory chain blockers, rotenone and 
oligomycin A (R/O), a model of ROS generation; (b) protein 
phosphatase inhibitor okadaic acid (OA), as model of 
hyperphosphorylation of tau protein; (c) β-amyloid peptides 
(Aβ25-35), involved in ROS and apoptosis pathways. Overall, the 
data obtained for compounds 1-7 revealed an interesting 
neuroprotection profile (see Supporting Information). At the 
lowest concentration tested (0.3 µM), contilisant offered 
significant neuroprotection against the toxic insults assayed (70% 
vs. R/O, 47% vs. OA and 65% vs. Aβ25-35) comparable to 
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Figure 2. Neuroprotective capabilities of contilisant (0.3 µM), ASS234 (5 µM) 
and melatonin (0.01 µM) in SH-SY5Y cells following rotenone 
30 µM/oligomycin A 10 µM (R/O), okadaic acid 20 nM (OA) or β amyloid peptide 
30 µM (Aβ25-35) intoxications, respectively. Data expressed as % 
neuroprotection ± SEM of at least four different cultures performed in triplicates 
(untreated control set to 100%). ***p≤0.001, **p≤0.01, *p≤0.05 compared to 
control.  
those of melatonin (Figure 2). Memory behaviour improvements 
after ASS234 and contilisant were tested in vivo using the novel 
object recognition test (NOR) in mice (Figure 3),[30]  before and 
after administration of lipopolysaccharide (LPS) that significantly 
impaired NOR performance. Mice treated with contilisant after 
LPS impairment showed a significantly improved discrimination 
index, but ASS234 (at the same dose) was not able to restore the 
cognitive deficit.  
  
 
Table 1.  IC50 and Ki values for the inhibition of hMAO A/B, hAChE/hBuChE and hH3R/hH4R, respectively, and ORAC analysis of compounds 1-7, 
ASS234, ciproxifan, clorgyline, deprenyl and donepezil. 
MTDL Preinc 
(min) 
hMAO A 
IC50[a] 
(µM) 
hMAO B 
IC50[a] 
(µM) 
SR 
MAO[b] 
 
hAChE 
IC50[a] 
(µM) 
hBuChE 
IC50[a] 
(µM) 
SR 
ChE[c] 
ORAC[d] 
(TE) 
hH3R 
Ki[e] 
(nM) 
hH4R 
Ki 
(nM) 
1 0 
30 
3.00±0.34 
0.095±0.009 
5.21±0.82 
0.140±0.008 
1.7 
1.5 
37.9±1.5 25.1±5.5 1.5 3.11±0.07 178 
[44, 716] 
>10,000 
2 0 
30 
4.01±0.60 
0.073±0.006 
1.80±0.24 
0.100±0.020 
0.5 
1.4 
18.8±2.7 7.40±1.41 2.5 4.54±0.08 4.5 
[1.8, 11] 
>10,000 
3 0 
30 
0.41±0.03 
0.052±0.007 
1.32±0.21 
0.017±0.003 
3.2 
0.3 
20.6±3.6 8.55±1.48 2.4 1.86±0.06 38.5 
[13, 117] 
>10,000 
4  
(contilisant) 
0 
30 
1.85±0.21 
0.145±0.010 
 1.94±0.15 
0.078±0.006 
1.0 
0.5 
0.53±0.05 1.69±0.12 0.3 3.59±0.09 10.8 
[4.2, 27] 
>100,000 
5 0 
30 
6.52±0.52 
0.166±0.015 
41.3±5.5 
4.65±0.06 
6.3 
28 
8.3±2.4 3.30±0.71 2.5 2.94±0.04 77.7 
[19, 311] 
>10,000 
6 0 
30 
1.19±0.15 
0.042±0.004 
3.80±0.40 
2.75±0.51 
3.2 
65 
58.3±11.8 31.1±1.8 1.9  14.7 
[3.8, 57] 
>10,000 
7 0 
30 
103±20 
91±1 
12.6±1.0 
11.2±0.9 
0.1 
0.1 
20.4±2.0 11.6±1.3 1.8 1.40±0.14 24.4 
[12, 50] 
>10,000 
ASS234 0 
30 
0.033±0.003 
0.00027±0.00003 
3.20±0.41 
0.12±0.02 
97 
444 
 
0.81 ± 0.06 
 
1.82±0.14 
 
0.4 
 
 
84.2 
[48, 149] 
>10,000 
Ciproxifan 0 11.4±1.2[15] 2.1±0.3[15] 0.2 86.1±20.9 77.3±3.4 1.1  46-180[22–24] >10,000[23] 
Clorgyline 0 
30 
0.042 ± 0.003 
0.00042±0.00008 
3.65±0.39 
3.57±0.36 
86 
8500 
not active[25] not active[25]     
Deprenyl 0 
30 
225±31 
0.630±0.086 
0.053±0.005 
0.0040±0.0009 
0.0002 
0.006 
 
not active[25] not active[25]     
Donepezil[4] 0    0.011 ± 0.001 6.22 ± 0.77 0.002    
[a] The error (SE) is indicated for each value; [b] SR= IC50 hMAO B/hMAO A; [c] SR = IC50 hAChE/hBuChE; [d] Oxygen Radical Absorbance Capacity 
[Trolox equivalents (TE)]; [e] The confidence interval (95%) is given in square brackets 
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Figure 3. Effects of contilisant and ASS234 on lipopolysaccharide (LPS)-
induced memory impairment in the novel object recognition test in mice. 
***p≤0.001, *p≤0.05, ns p>0.05. 
In conclusion, new MDLs showing inhibitory properties for 
neurotransmitter-catabolizing enzymes (ChEs and MAOs) 
alongside H3R affinity, are described for the first time. From this 
small series, contilisant showed best overall multitargeting 
properties in nanomolar concentration ranges, with newly 
designed-in and well-balanced properties of permeation as well 
as antioxidant and neuroprotective capacity. Contilisant provides 
a pharmacological profile with improved complexity, possibly 
beneficial for treatment of neurodegenerative conditions. 
Compared to the dual targeting H3R/MAO ligand, ciproxifan[15]  
contilisant is a more potent inhibitor of MAO with irreversible 
binding properties. Moreover, contilisant at 1 mg/kg restored the 
cognitive deficit of LPS-treated mice.  
As intended, all properties of the small molecule MDL 
contilisant (4) were optimized compared to those of lead 
compound ASS234, including reduced inhibition of MAO A, and 
successfully extended by high H3R affinity by taking advantage of 
the structural blue print for H3R pharmacophores.[31] The resulting 
unique pharmacological profile, addressing various targets 
involved in neurodegenerative processes, may be suitable for 
treatment of Alzheimer´s or Parkinson´s diseases. 
Experimental Section 
Experimental procedures including, synthesis, analytics, pharmacological 
assays and modelling studies are available under http://dx.doi.org/. 
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Hitting multiple targets at once: 
Therapy of multifactorial disease 
conditions needs to address multiple 
targets, an especial challenge for 
neurodegenerative diseases. 
Designing multitarget-directed ligands 
able to cross the blood brain barrier is 
a complex task in medicinal chemistry. 
We described small molecule ligands 
affecting four neurotransmitter-
catabolizing enzymes as well as the 
histamine H3 receptor as pro-cognitive 
G-protein coupled receptor.  
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